Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The ribonucleic acid (rna)-based oncolytic therapy market has experienced rapid expansion in recent years. This market is projected to increase from $2.12 billion in 2025 to $2.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 18.7%. Historically, this growth was influenced by advancements in cancer virology research, a deeper understanding of tumor immunology, the availability of clinical trial infrastructure, a rise in oncology research funding, and the early success seen in oncolytic virus studies.
The ribonucleic acid (rna)-based oncolytic therapy market size is projected to experience substantial expansion over the upcoming years. This market is set to reach $4.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.4%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing approvals of rna-based cancer therapies, a growing demand for personalized oncology treatments, the expansion of immuno-oncology pipelines, rising investment in gene and cell therapies, and progress in rna delivery system technologies. Key trends anticipated for the forecast period encompass the escalating advancement of rna virus engineering, a rise in the adoption of combination oncolytic therapies, an intensified focus on activating the immune system, the broadening of targeted tumor-specific rna therapies, and improved integration of precision oncology tools.
Get A Free Sample Report With In-Depth Market Insights:
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Growth Backed By Core Demand Fundamentals
The increasing embrace of personalized medicine is anticipated to fuel the expansion of the RNA-based oncolytic therapy market in the coming period. This approach involves medical interventions specifically crafted for a patient’s unique genetic makeup, leading to enhanced effectiveness and fewer negative side effects. Its uptake is rising because a greater number of healthcare entities and practitioners acknowledge its capacity to improve patient results via focused treatments and accurate diagnostic methods. RNA-based oncolytic therapy holds a significant position in cancer treatment, complementing the rise of personalized medicine to offer therapies that are both targeted and specific to individual patients. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based advocacy group advocating for customized medical solutions, reported that the FDA sanctioned 16 novel personalized treatments for patients with rare diseases in 2023, an increase from 6 approvals in 2022. Consequently, the escalating acceptance of personalized medicine is a key driver for the RNA-based oncolytic therapy market.
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Segment Landscape: Which Areas Lead Development?
The ribonucleic acid (rna)-based oncolytic therapy market covered in this report is segmented –
1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types
2) By Route Of Administration: Intravenous, Intratumoral, Other Route Of Administrations
3) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications
4) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users
Subsegments:
1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy
2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA
3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys
4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Growth Trends Reshaping The Competitive Landscape
Leading companies operating in the ribonucleic acid (RNA)-based oncolytic therapy market are concentrating on developing technological advancements, notably synthetic messenger RNA (mRNA) technology, to boost tumor-targeting efficiency, enhance immune activation, and achieve more precise and durable cancer treatment results. Synthetic messenger RNA (mRNA) technology represents a biotechnology approach that involves designing and delivering lab-made mRNA sequences to direct cells in producing specific therapeutic proteins for disease treatment, including cancer. For instance, in June 2024, CSPC Pharmaceutical Group Limited, a China-based pharmaceutical company, received regulatory approval in China to commence clinical trials for SYS6020, its synthetic mRNA-based cancer cell therapy. This development signifies a major progression in the country’s messenger RNA therapeutics landscape. SYS6020 employs mRNA-lipid nanoparticle technology to selectively target and eliminate myeloma cancer cells with minimal adverse effects, while also demonstrating potential applications in the treatment of certain autoimmune diseases.
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Industry Leaders And Competitive Landscape
Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.
View The Full Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report:
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna)-based oncolytic therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
